DNA hypomethylating agents increase activation and cytolytic activity of CD8

CD8-Positive T-Lymphocytes / immunology CpG Islands / immunology DNA Methylation / drug effects Decitabine / pharmacology Granzymes / immunology Humans Lymphocyte Activation / drug effects NFATC Transcription Factors / immunology Perforin / immunology
CD8+ T cells DNA methylation NFATc1 cytolytic activity decitabine epigenetic therapy granzyme B killing potential

Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
01 04 2021
Historique:
received: 12 06 2020
revised: 16 12 2020
accepted: 27 01 2021
pubmed: 21 2 2021
medline: 15 4 2021
entrez: 20 2 2021
Statut: ppublish

Résumé

We demonstrate that DNA hypomethylating agent (HMA) treatment can directly modulate the anti-tumor response and effector function of CD8

Identifiants

DOI: 10.1016/j.molcel.2021.01.038 PMID: 33609448
pubmed: 33609448
pii: S1097-2765(21)00058-7
doi: 10.1016/j.molcel.2021.01.038
pii:
doi:

Substances chimiques

NFATC Transcription Factors 0
NFATC1 protein, human 0
Perforin 126465-35-8
Decitabine 776B62CQ27
GZMB protein, human EC 3.4.21.-
Granzymes EC 3.4.21.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1469-1483.e8

Subventions

Organisme : CIHR
ID : 201512MSH360794-228629
Pays : Canada
Organisme : CIHR
ID : FDN 148430
Pays : Canada
Organisme : CIHR
ID : PJT 165986
Pays : Canada
Organisme : CIHR
ID : FDN148386
Pays : Canada
Organisme : CIHR
ID : MFE-164724
Pays : Canada

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests D.D.D.C. received research funds from Pfizer and Nektar Therapeutics. D.D.D.C. is a co-founder and shareholder of DNAMx, Inc. C.K. is employed by and owns stock, patents, and royalties with Roche. J.S. is a permanent scientific advisory board member for and owns stock in Surface Oncology.

Auteurs

Helen Loo Yau (H)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.

Emma Bell (E)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.

Ilias Ettayebi (I)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.

Felipe Campos de Almeida (FC)

Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, Brazil; Instituto de Investigação em Imunologia, Institutos Nacionais de Ciência e Tecnologia (INCT-iii), São Paulo 05403-900, Brazil.

Giselle M Boukhaled (GM)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada.

Shu Yi Shen (SY)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.

David Allard (D)

Centre de recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Montréal, QC H2X 0A9, Canada; Faculté de Pharmacie, Université de Montréal, Montréal, QC H3T 1J4, Canada.

Beatriz Morancho (B)

Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO) and CIBERONC, 08035 Barcelona, Spain.

Sajid A Marhon (SA)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.

Charles A Ishak (CA)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.

Isabela M Gonzaga (IM)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.

Tiago da Silva Medina (T)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Translational Immuno-oncology Laboratory, A.C. Camargo Cancer Center, São Paulo 01509-001, Brazil.

Rajat Singhania (R)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.

Ankur Chakravarthy (A)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.

Raymond Chen (R)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.

Parinaz Mehdipour (P)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.

Sandra Pommey (S)

Centre de recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Montréal, QC H2X 0A9, Canada.

Christian Klein (C)

Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Wagistrasse 10, 8952 Schlieren, Switzerland.

Gustavo P Amarante-Mendes (GP)

Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, Brazil; Instituto de Investigação em Imunologia, Institutos Nacionais de Ciência e Tecnologia (INCT-iii), São Paulo 05403-900, Brazil.

David Roulois (D)

UMR U1236, INSERM, Université de Rennes 1, EFS, 35000 Rennes, France.

Joaquín Arribas (J)

Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO) and CIBERONC, 08035 Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.

John Stagg (J)

Centre de recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Montréal, QC H2X 0A9, Canada; Faculté de Pharmacie, Université de Montréal, Montréal, QC H3T 1J4, Canada.

David G Brooks (DG)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada.

Daniel D De Carvalho (DD)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada. Electronic address: daniel.decarvalho@uhnresearch.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › DNA hypomethylating agents increase activation...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Ilots CpG › DNA hypomethylating agents increase activation...
questionsmedicales.fr › Phénomènes génétiques › Méthylation de l'ADN › DNA hypomethylating agents increase activation...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Ribonucléosides › Cytidine › Azacitidine › Décitabine › DNA hypomethylating agents increase activation...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Protéases à sérine › Serine endopeptidases › Granzymes › DNA hypomethylating agents increase activation...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › DNA hypomethylating agents increase activation...
questionsmedicales.fr › Phénomènes du système immunitaire › Activation des lymphocytes › DNA hypomethylating agents increase activation...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription NFATC › DNA hypomethylating agents increase activation...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Perforines › Perforine › DNA hypomethylating agents increase activation...